European review for medical and pharmacological sciences
-
Eur Rev Med Pharmacol Sci · Mar 2017
The role of miR-146a in modulating TRAF6-induced inflammation during lupus nephritis.
Lupus nephritis (LN) is a major complication of systemic lupus erythematosus (SLE). A previous study showed decreased expression level of microRNA (miR)-146a in LN patients, indicating its possible role in LN pathogenesis. ⋯ The expression of miR-146a in renal tissues of LN patients was significantly depressed, while the transcriptional activity of TRAF6 and NF-κB was enhanced. MiR-146 thus inhibited NF-κB transcriptional activity and inflammatory factor synthesis, and alleviated chemotactic effect towards macrophage via the inhibition of TRAF6 activity.
-
Eur Rev Med Pharmacol Sci · Feb 2017
Comparative StudyCould MRI visualize the invisible? An Italian single center study comparing magnetic resonance lymphography (MRL), super microsurgery and histology in the identification of lymphatic vessels.
Aim of this study is to evaluate the possibility of limb magnetic resonance lymphography (MRL) to differentiate lymphatic vessels from pathological veins, collect a specimen of the identified lymphatic vessel during operations of super microsurgical lymphatic-venular anastomosis (s-LVA) and perform immunohistochemical stainings to confirm the nature of the collected vessels. ⋯ Most of the articles in the international literature report the concomitant presence of both lymphatic and venous vessels at MRL. However, no one in literature describes the possibility to differentiate venous vessels from lymphatic vessels, and this is a crucial issue for the correct evaluation of the lymphatic system in patients with limb lymphedema undergoing a future surgical correction. In the present study, MRL allowed to identify active lymphatic vessels. MRL was predictive to determine preoperatory lymphatic vessels and to perform successful s-LVA in lymphedema patients. This is the first study to prove the nature of the vessels identified at the preoperative MRL with immunohistochemical stainings.
-
Eur Rev Med Pharmacol Sci · Jan 2017
Meta AnalysisA meta-analysis of efficacy and safety of catheter-directed interventions in submassive pulmonary embolism.
Catheter-directed interventions, such as catheter-directed thrombolysis (CDT), are becoming a popular therapeutic option for patients with hemodynamically stable pulmonary embolism (PE) and right ventricle (RV) dysfunction (submassive PE). We wished to quantitatively assess therapeutic efficacy and safety of catheter-directed interventions in submassive PE. ⋯ This meta-analysis demonstrates evidence of therapeutic efficacy and low rates of adverse events of catheter-directed interventions in submassive PE.
-
Eur Rev Med Pharmacol Sci · Jan 2017
NF-κB/P65 signaling pathway: a potential therapeutic target in postoperative cognitive dysfunction after sevoflurane anesthesia.
This study aimed to explore the role of NF-κB/P65 signaling pathway in postoperative cognitive dysfunction (POCD) after sevoflurane anesthesia. ⋯ These results suggest that the inhibition of NF-κB/P65 signaling pathway may relieve POCD after sevoflurane anesthesia.
-
Eur Rev Med Pharmacol Sci · Dec 2016
Movardol® (N-acetylglucosamine, Boswellia serrata, ginger) supplementation in the management of knee osteoarthritis: preliminary results from a 6-month registry study.
Knee Osteoarthritis (OA) is a chronic disease caused by the deterioration of cartilage in joints, which results in activation of the inflammatory response, pain, and impaired movement. Complementary therapies, particularly supplementation, in the management of moderate/severe knee OA have been gaining attention. This registry study aimed at evaluating the synergistic effect of Movardol®, a supplementation containing active ingredients with recognized anti-inflammatory activities on symptoms and levels of circulating biomarkers of knee OA. ⋯ These preliminary results indicate the efficacy and safety of Movardol® supplementation in the management of moderate knee OA.